AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03097796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042
Description: PUL-042 Inhalation Solution
Study NCT06264609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.
Study NCT06264609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.
Study NCT06264609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
Study NCT05539326 — intervention group
Intervention type: OTHER
Intervention: Performance Clinical Outcome Test
Description: Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
Study NCT06653842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTORIN 3.9% rapamycin anhydrous gel
Description: QTORIN 3.9% Rapamycin Anhydrous Gel
Study NCT05659849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy techniques
Description: Passive joint mobilization techniques are applied to the affected knee joint. For the first week (three sessions), the joint mobilization exercises included grade I or II rhythmic oscillations. During the following weeks, grade III or IV oscillation techniques were applied, depending on the level of tolerance and pain of each patient. In knee distraction, the patients are in a prone position with 50° knee flexion, and the physical therapist applies the techniques. The dorsal and ventral glides was performed with the patient in a supine position.
Study NCT05659849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) therapy treats pain using low-voltage electric currents. A small device administers the electrical current to or near nerves. TENS treatment inhibits or changes pain perception.
Study NCT05212792 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccines
Description: Any licensing COVID-19 vaccine platform
Study NCT05762432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound Dressing
Description: RTD Wound Dressing that is being investigated
Study NCT05762432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHS Standard Dressing
Description: This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
Study NCT06248151 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise session
Description: Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups
Study NCT06248151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise session
Description: Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups
Study NCT06248151 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control session
Description: Remain seated for 60 min
Study NCT06248151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control session
Description: Remain seated for 60 min
Study NCT06712017 — intervention group
Intervention type: DEVICE
Intervention: Yttrium-90 (Y-90) resin microspheres
Description: selective internal radiation therapy
Study NCT06717022 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHT102 allogeneic CAR T cells
Description: CHT102 allogeneic CAR T cells
Study NCT06718127 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood samples collection
Description: blood samples collected at D0 ,W1, W5, M3 and M6
Study NCT06195826 — intervention group
Intervention type: PROCEDURE
Intervention: Gravity infusion
Description: hysteroscopic myomectomy with the gravity infusion method
Study NCT06195826 — intervention group
Intervention type: PROCEDURE
Intervention: Pump infusion
Description: hysteroscopic myomectomy with the pump infusion method
Study NCT06044194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine and liposomal vitamin C
Description: Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
Study NCT06718504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Glasses
Description: Virtual reality is a method that can be used to distract and prepare patients for medical procedures. Virtual reality is a computer-generated environment where three-dimensional interaction is possible. It is an advanced technology that allows an individual to move into a virtual environment and focus their attention on other thoughts, allowing them to pay less attention to pain and anxiety. In this study, the virtual reality glasses were put on for the intervention group five minutes before the procedure began and were kept on until the procedure was completed. The virtual reality glasses showed the patient-selected images of a relaxing nature setting or images without any violent content.
Study NCT06715865 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thymus Transplantation
Description: Thymus Transplantation
Study NCT06718205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Combined chemotherapy phase Nimotuzumab 400mg，I.V.，D1，QW Maintenance treatment period:Until unbearable or PD Nimotuzumab 400mg，I.V.，D1，Q3W
Study NCT06718205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg，I.V.，D1，Q3W，Until unbearable or PD
Study NCT06718205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin 200 mg/m2，I.V.，D1，Q3W，4-6 Cycle
Study NCT06718205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin:75 mg/m2，I.V.，D1,Q3W，4-6 Cycle
Study NCT06716398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product
Description: Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
Study NCT06716398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator product
Description: Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
Study NCT06716216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 5 mg BGM0504 Administered SC
Description: Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Study NCT06716216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug:10 mg BGM0504 Administered SC
Description: Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
Study NCT06716216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Semaglutide Administered SC
Description: Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week
Study NCT06717542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: histochemical and immunohistochemical analysis
Description: 2 µm sections will be cut from the paraffin blocks for histochemical and immunohistochemical (IHC) investigations. IHC will be performed with an automated stainer (Ventana/Roche®, Ventana Medical Systems, USA) for the endothelial markers CD34, ERG, Nestin and Caveolin-1
Study NCT06717542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RT-PCR
Description: Custom RT-PCR analyses will be performed manually for the transcripts (mRNA) of the ERG, Nestin, VEGFR and other genes, at the Pathology Anatomy lab hall. 18 (Prof. D'Errico). Total RNA will be extracted from the paraffin blocks with the RecoverAll™ Total Nucleic Acid Isolation kit (Invitrogen). Reverse Transcriptase will be performed with the High Capacity Reverse Transcription kit (Life Technologies), using the specific primers. Real-Time PCR will be performed with the CFX Connect Real-Time PCR Identification System (BioRad).
Study NCT03786237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib Oral Capsules / Rigosertib Intravenous
Description: Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter.
Study NCT04721067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHUTi
Description: SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
Study NCT04721067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education/Hygiene
Description: A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
Study NCT05692024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
Description: Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
Study NCT05692024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
Study NCT04747743 — intervention group
Intervention type: OTHER
Intervention: a self structured questionnaire
Description: A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
Study NCT05582161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
Study NCT05088954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal epidural steroid injection
Description: In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive education
Description: The research team will use psychology and communications research to present information about seat belts and distracted driving in a way that builds intrinsic motivation to change. Because positively framed messages are more effective at promoting seat belt wearing, the team's messaging will employ this framing. Education will address common reasons that survey participants give for not consistently buckling up or for phone use while driving.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)
Description: Participants will receive an intervention on improving driving behavior with a specific goal in mind and how to reach that goal. Participants will do this by thinking through 4 parts: a wish, an outcome, an obstacle and a plan. This has been shown to build motivation, and help achieve the desired change.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Habit Tips
Description: Participants will receive weekly text-message tips, informed by findings from survey responses, plus reminders to address stated obstacles.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raffle Financial Incentive
Description: Each week, participants who adhere to seat belt use or abstain from phone use while driving get a chance at prize money. One winner will be randomly chosen for each target behavior and earn prize money; the rest will not receive compensation.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Pot Financial Incentive
Description: This will be identical to the raffle incentive, except that each week participants who adhere to seat belt use or abstain from phone use while driving will be guaranteed an equal share of prize money.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly SMS Support text
Description: Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weekly SMS Support text
Description: Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
Study NCT05469477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly SMS Encouragement
Description: Those who have a perfect streak going midway through each week will receive an additional encouraging message cheering them on.
Study NCT04700852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puressentiel protective nasal spray
Description: provocative nasal test with grass pollen and nasal lavage
Study NCT06379867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: 0.4 mg/kg, IV bolus administration
Study NCT06379867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV bolus administration
Study NCT06379867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 0.4 g, Oral administration with 240 mL
Study NCT04912791 — intervention group
Intervention type: PROCEDURE
Intervention: Obstetric anesthesia and analgesia
Description: All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
Study NCT05618444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Management (AM)
Description: A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
Study NCT05910567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Focused Assessment with Sonography for Trauma (FAST) Examination
Description: A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
Study NCT05910567 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention: Standard of Care - Without the FAST Examination
Description: Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
Study NCT05457595 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiation therapy
Description: CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted.
Study NCT05986929 — intervention group
Intervention type: OTHER
Intervention: focus group
Description: Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
Study NCT05986929 — intervention group
Intervention type: OTHER
Intervention: electronic survey
Description: An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
Study NCT04696146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berinert
Description: Intrarenal dose of 500 U of Berinert
Study NCT04696146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline placebo
Study NCT06270407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 100 MG/ML
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
Study NCT06270407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
Study NCT06093087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAIF
Description: The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height
Study NCT06093087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BKP
Description: The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.
Study NCT02575508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02575508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02575508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02575508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02575508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pan FGFR Kinase Inhibitor BGJ398
Description: Given IV
Study NCT02575508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT05678231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero Degree Knee Positioner
Description: The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
Study NCT05688969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early versus late biopsy
Description: early (3-6 weeks) versus late (6-8 months) biopsy
Study NCT06455176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar cleft Grafting from the symphysis
Description: grafting using particulate bone from the symphysis